Journal of Neuro-Oncology

, Volume 140, Issue 2, pp 359–366 | Cite as

Prediction value of unmeasurable MR enhancement at early stage after gross-total resection on the survival state of patients with high-grade glioma

  • Guanmin Quan
  • Yongli Zheng
  • Jun Chen
  • Bei Hua
  • Xiaoli Ji
  • Kexin Zhang
  • Duo Gao
  • Jianming Lei
  • Tao YuanEmail author
Clinical Study



To explore the value of unmeasurable enhancement pattern of residual cavity in predicting survival at early stage after gross-total resection in high-grade glioma (HGG) patients.


This retrospective study enrolled consecutive 51 HGG patients with unmeasurable enhancement who underwent gross-total resection followed by concurrent chemoradiotherapy and adjuvant chemotherapy. We evaluated the enhancement patterns of residual cavity on contrast-T1WI made within 1 month after tumor resection (20 ± 3 days). The survival state of different enhancement was compared.


Thin-linear, thick-linear and nodular enhancement were observed in 22 patients (43%), 10 patients (20%), and 19 patients (37%), respectively. The progression-free survival of patients with thin-linear (487, 151–887 days) was longer than those patients with thick-linear (277, 133–573 days), and nodular enhancement (210, 120–765 days) (P = 0.002). The overall survival of patients with thin-linear (774, 457–1343 days) was longer than those with thick-linear (462, 320–678 days), and nodular enhancement (326, 234–1393 days) (P = 0.002). There was no significant difference of orthogonal value between thick-linear and nodular enhancement (0.854), neither between grade III and IV with same enhancement patterns (P = 0.540, P = 0.720).


The unmeasurable enhancement patterns in HGG patients within 1 month after gross-total resection, which might be better than the grade of tumor, holds a potential marker in survival state.


Glioma Chemoradiotherapy Outcome Magnetic resonance imaging Enhancement 


Compliance with ethical standards

Conflict of interest

The authors report no conflicts of interest.


  1. 1.
    Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefGoogle Scholar
  2. 2.
    Kim R, Choi SH, Yun TJ et al (2017) Prognosis prediction of non-enhancing T2 high signal intensity lesions in glioblastoma patients after standard treatment: application of dynamic contrast-enhanced MR imaging. Eur Radiol 27:1176–1185CrossRefGoogle Scholar
  3. 3.
    Clarke JL, Molinaro AM, Phillips JJ et al (2014) A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma. Neuro Oncol 16:984–990CrossRefGoogle Scholar
  4. 4.
    Bette S, Gempt J, Huber T et al (2017) FLAIR signal increase of the fluid within the resection cavity after glioma surgery: generally valid as early recurrence marker? J Neurosurg 127:417–425CrossRefGoogle Scholar
  5. 5.
    Sanz-Requena R, Revert-Ventura AJ, García-Martí G et al (2017) Post-treatment changes of tumour perfusion parameters can help to predict survival in patients with high-grade astrocytoma. Eur Radiol 27:3392–3400CrossRefGoogle Scholar
  6. 6.
    Cui Y, Li G, Yan M et al (2017) The effects of gene polymorphisms on glioma prognosis. J Gene Med 19:e2989CrossRefGoogle Scholar
  7. 7.
    Ackerl M, Flechl B, Dieckmann K et al (2014) Outcome evaluation in glioblastoma patients older than 65 years: importance of individual assessment of treatment tolerance. Clin Neuropathol 33:399–406CrossRefGoogle Scholar
  8. 8.
    Switzeny OJ, Christmann M, Renovanz M, Giese A, Sommer C, Kaina B (2016) MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response. Clin Epigenetics 8:49CrossRefGoogle Scholar
  9. 9.
    Choi YS, Kim DW, Lee SK et al (2015) The added prognostic value of preoperative dynamic contrast-enhanced MRI histogram analysis in patients with glioblastoma: analysis of overall and progression-free survival. Am J Neuroradiol 36:2235–2241CrossRefGoogle Scholar
  10. 10.
    Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972CrossRefGoogle Scholar
  11. 11.
    Yoo R, Choi SH, Kim TM et al (2017) Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study. Eur Radiol 27:3156–3166CrossRefGoogle Scholar
  12. 12.
    Chu HH, Choi SH, Ryoo I et al (2013) Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging. Radiology 269:831–840CrossRefGoogle Scholar
  13. 13.
    Kim BR, Choi SH, Yun TJ et al (2016) MR imaging analysis of non-measurable enhancing lesions newly appearing after concomitant chemoradiotherapy in glioblastoma patients for prognosis prediction. PLoS ONE 11:e0166096CrossRefGoogle Scholar
  14. 14.
    Majós C, Cos M, Castañer S et al (2016) Early post-operative magnetic resonance imaging in glioblastoma: correlation among radiological findings and overall survival in 60 patients. Eur Radiol 26:1048–1055CrossRefGoogle Scholar
  15. 15.
    Swarm R, Pickar A, Anghelescu A, Benedetti C, Buga S, Cleeland C (2006) NCCN Clinical Practice Guidelines in Oncology™. JNCCN 8:1046–1086Google Scholar
  16. 16.
    Quigley MR (1994) Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and influence on regrowth and prognosis. Neurosurgery 34:1105Google Scholar
  17. 17.
    Ekinci G, Akpinar IN, Baltacioğlu F et al (2003) Early-postoperative magnetic resonance imaging in glial tumors: prediction of tumor regrowth and recurrence. Eur J Radiol 45:99–107CrossRefGoogle Scholar
  18. 18.
    Gzell CE, Wheeler HR, Mccloud P, Kastelan M, Back M (2016) Small increases in enhancement on MRI may predict survival post radiotherapy in patients with glioblastoma. J Neurooncol 128:67–74CrossRefGoogle Scholar
  19. 19.
    Warnke PC, Kreth FW, Ostertag CB (1995) Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 36:872–874CrossRefGoogle Scholar
  20. 20.
    Farace P, Amelio D, Ricciardi GK et al (2013) Early MRI changes in glioblastoma in the period between surgery and adjuvant therapy. J Neurooncol 111:177–185CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.The Second Hospital of Hebei Medical UniversityShijiazhuangChina

Personalised recommendations